









Markets
/
Stocks
/
nasdaq-aciu
/

AC Immune SA

ACIU

2.520USD

+0.060+2.44%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

253.03MMarket Cap

LossP/E TTM



AC Immune SA

2.520

+0.060+2.44%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

71 / 507

Overall Ranking

181 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Strong Buy

Current Rating

9.000

Target Price

+254.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 607.16% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 30.10M.

Undervalued

The company’s latest PE is -5.71, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 63.69M shares, decreasing 5.43% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 828.32K shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 6.22, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.65M, representing a year-over-year increase of 115.44%, while its net profit experienced a year-over-year increase of 5.51%.

Score

Industry at a Glance

Previous score

5.76

Change

0.46



Financials

4.89

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.71

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.66

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.33

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -5.71, which is -41.76% below the recent high of -3.33 and 11.24% above the recent low of -5.07.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 71/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 9.33, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for AC Immune SA is 8.50, with a high of 12.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

9.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Strong Buy

Current Rating

9.000

Target Price

+265.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

AC Immune SA

ACIU

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 8.47, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 2.69 and the support level at 2.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.95

Change

-0.48

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.067

Buy

RSI(14)

63.334

Neutral

STOCH(KDJ)(9,3,3)

83.437

Neutral

ATR(14)

0.152

High Vlolatility

CCI(14)

105.499

Buy

Williams %R

12.500

Overbought

TRIX(12,20)

0.570

Sell

StochRSI(14)

44.649

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.486

Buy

MA10

2.389

Buy

MA20

2.254

Buy

MA50

2.208

Buy

MA100

2.018

Buy

MA200

2.232

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 63.43%, representing a quarter-over-quarter decrease of 1.58%. The largest institutional shareholder is James Simons, holding a total of 828.32K shares, representing 0.82% of shares outstanding, with 11.90% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

19.82M

+1.54%

DH Capital GmbH & Co. KG

16.32M

Varuma AG

12.00M

Affiris AG

6.43M

-2.28%

Pfeifer (Andrea M. A Ph.D.)

2.96M

+22.09%

Wells Fargo Advisors

997.62K

+0.20%

Renaissance Technologies LLC

Star Investors

803.47K

+8.55%

Acadian Asset Management LLC

371.18K

+87.10%

Northern Trust Global Investments Limited

377.09K

-6.44%

BlackRock Institutional Trust Company, N.A.

393.51K

-7.46%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.16, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.50. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.